AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22999717 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (12‐month DAPT), n=1058
Number of subjects: 2117
Study 20220747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0
Study 20220747 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus
Number of subjects: 0
Study 17978849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsterile gel
Number of subjects: 60
Study 17978849 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline
Number of subjects: 60
Study 17978849 — intervention group
Group type: COMPARATOR
Intervention: Povidine-iodine
Number of subjects: 60
Study 15901604 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative assessment (data collection by a respiratory therapist with repeat assessment after 2 months of stability)
Number of subjects: 546
Study 15901604 — intervention group
Group type: COMPARATOR
Intervention: Conventional assessment (data collected by oxygen providers and judgments by Home Oxygen Program personnel)
Number of subjects: 546
Study 12407043 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 50 mg on days 2-6
Number of subjects: 35
Study 12407043 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate 50 mg on days 5-9
Number of subjects: 35
Study 10428533 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (n = 17)
Number of subjects: 33
Study 10428533 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33
Study 8532497 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentionally highlighted event structure with accents coinciding with grammatical phrase boundaries (Experiment 1 and 2)
Number of subjects: 0
Study 8532497 — intervention group
Group type: EXPERIMENTAL
Intervention: Obscured event structure with accents conflicting with grammatical phrase boundaries (Experiment 1 and 2)
Number of subjects: 0
Study 1730330 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist (GnRH-a) deslorelin, 300 micrograms daily for 4 months
Number of subjects: 26
Study 1730330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6699892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tutored videotape-instruction (TVI)
Number of subjects: 0
Study 6699892 — intervention group
Group type: COMPARATOR
Intervention: Live lectures
Number of subjects: 0
Study 31525148 — intervention group
Group type: EXPERIMENTAL
Intervention: Who Do You Tell?™ child sexual abuse education program
Number of subjects: 6198
Study 29768149 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol) used as needed
Number of subjects: 3849
Study 29768149 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg) used as needed
Number of subjects: 3849
Study 29768149 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (200 μg) plus terbutaline used as needed
Number of subjects: 3849
Study 26704966 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickened extensively casein hydrolyzed protein formula (T-eCHF)
Number of subjects: 71
Study 26704966 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-thickened extensively casein hydrolyzed protein formula (NT-eCHF)
Number of subjects: 71
Study 23171140 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic trainer box warm-up
Number of subjects: 109
Study 23171140 — intervention group
Group type: EXPERIMENTAL
Intervention: PlayStation 2 warm-up
Number of subjects: 109
Study 23171140 — intervention group
Group type: COMPARATOR
Intervention: No warm-up
Number of subjects: 109
Study 24140183 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg per day
Number of subjects: 81
Study 24140183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 21129474 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tangzu Yuyang Ointment (TYO) plus standard wound therapy (SWT)
Number of subjects: 57
Study 21129474 — intervention group
Group type: COMPARATOR
Intervention: Standard wound therapy (SWT)
Number of subjects: 57
Study 20467528 — intervention group
Group type: EXPERIMENTAL
Intervention: Home walking program (30 min, 3 times a week for 12 weeks)
Number of subjects: 12
Study 20467528 — intervention group
Group type: COMPARATOR
Intervention: Control group (refrained from any regular exercise)
Number of subjects: 12
Study 17452166 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release paroxetine
Number of subjects: 14
Study 15646732 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol treatment
Number of subjects: 0
Study 11496277 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 2650
Study 11496277 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2650
Study 9510396 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFNalpha) therapy
Number of subjects: 100
Study 9510396 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 patients)
Number of subjects: 100
Study 7493145 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0 micrograms (Group I)
Number of subjects: 75
Study 7493145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 7.5 micrograms (Group II)
Number of subjects: 75
Study 7493145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms (Group III)
Number of subjects: 75
Study 7493145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 12.5 micrograms (Group IV)
Number of subjects: 75
Study 7493145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 15 micrograms (Group V)
Number of subjects: 75
Study 7493145 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 75
Study 7493145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 12.5 micrograms or 15 micrograms
Number of subjects: 75
Study 7493145 — intervention group
Group type: EXPERIMENTAL
Intervention: Group IV & V
Number of subjects: 75
Study 2132678 — intervention group
Group type: EXPERIMENTAL
Intervention: Target slide with greater number of pairings with shock in the first series
Number of subjects: 20
Study 2132678 — intervention group
Group type: EXPERIMENTAL
Intervention: Random sequence of slide-shock trials in the second series
Number of subjects: 20
Study 2132678 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line probability estimates and electrodermal responding
Number of subjects: 20
Study 2132678 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariation bias
Number of subjects: 20
Study 7357809 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 45 mg
Number of subjects: 100
Study 7357809 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 90 mg
Number of subjects: 100
Study 7357809 — intervention group
Group type: COMPARATOR
Intervention: Propoxyphene 65 mg
Number of subjects: 100
Study 7357809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31922998 — intervention group
Group type: EXPERIMENTAL
Intervention: KDIGO bundle compliance
Number of subjects: 95
Study 31922998 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotoxic drugs discontinuation
Number of subjects: 95
Study 31922998 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume optimization
Number of subjects: 95
Study 31922998 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional hemodynamic monitoring
Number of subjects: 95
Study 31922998 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of serum creatinine and urine output
Number of subjects: 95
Study 31922998 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of hyperglycemia
Number of subjects: 95
Study 31922998 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of radiocontrast agents
Number of subjects: 95
Study 31922998 — intervention group
Group type: EXPERIMENTAL
Intervention: Average supportive measures received
Number of subjects: 95
Study 31922998 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of measures between AKI and non-AKI patients
Number of subjects: 95
Study 31260943 — intervention group
Group type: EXPERIMENTAL
Intervention: APT + usual care
Number of subjects: 24
Study 31260943 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 24
Study 28329211 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN‐003 (30 µg)
Number of subjects: 134
Study 28329211 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN‐003 (100 µg)
Number of subjects: 134
Study 28329211 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN‐003 (10 µg)
Number of subjects: 134
Study 28329211 — intervention group
Group type: COMPARATOR
Intervention: Antigens without adjuvant
Number of subjects: 134
Study 28329211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 25649717 — intervention group
Group type: EXPERIMENTAL
Intervention: SpHb Group (continuous noninvasive hemoglobin monitoring)
Number of subjects: 0
Study 25649717 — intervention group
Group type: COMPARATOR
Intervention: Control Group (intermittent blood sampling)
Number of subjects: 0
Study 23343318 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional-facilitated intervention (PFI; N=509)
Number of subjects: 835
Study 23343318 — intervention group
Group type: COMPARATOR
Intervention: Self-help (SH; N=326)
Number of subjects: 835
Study 21209231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg/day (2 × 100 mg tablets)
Number of subjects: 18
Study 21209231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 19216606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (0.2%)
Number of subjects: 44
Study 19216606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution (2%)
Number of subjects: 44
Study 19216606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (1%)
Number of subjects: 44
Study 19216606 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chlorhexidine treatment)
Number of subjects: 44
Study 17944273 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ribavirin
Number of subjects: 170000
Study 17944273 — intervention group
Group type: EXPERIMENTAL
Intervention: Promising new agents
Number of subjects: 170000
Study 15555479 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (9 months of support and 3 months of follow-up)
Number of subjects: 314
Study 15555479 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 314
Study 15555479 — intervention group
Group type: COMPARATOR
Intervention: Both groups (intervention and control)
Number of subjects: 314
Study 11574372 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.125% with sufentanil 0.75 microg/mL and epinephrine 1.25 microg/mL
Number of subjects: 80
Study 11574372 — intervention group
Group type: COMPARATOR
Intervention: Racemic bupivacaine 0.125% with sufentanil 0.75 microg/mL and epinephrine 1.25 microg/mL
Number of subjects: 80
Study 9634262 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam-distilled garlic oil preparation (5 mg twice a day)
Number of subjects: 25
Study 9634262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7945742 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medications with a placebo run-in period
Number of subjects: 101
Study 7945742 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medications with a post-randomization placebo treatment cell
Number of subjects: 101
Study 7945742 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 101
Study 1968233 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (alpha‐2‐adrenoceptor antagonist)
Number of subjects: 8
Study 1968233 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 8
Study 1968233 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 8
Study 1968233 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan and naloxone combination
Number of subjects: 8
Study 1968233 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan alone
Number of subjects: 8
Study 373439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus gentamicin (group 1)
Number of subjects: 0
Study 373439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus amikacin (group 2)
Number of subjects: 0
Study 373439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticarcillin plus netilmicin (group 3)
Number of subjects: 0
Study 30811963 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg)
Number of subjects: 18
Study 30811963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28011247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized arformoterol 15 µg BID
Number of subjects: 841
Study 28011247 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 841
Study 25880172 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 307
Study 25880172 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 307
Study 25880172 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 307
Study 23382470 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticorelin acetate (CrA) 1 mg twice per day
Number of subjects: 200
Study 23382470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 23382470 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticorelin acetate (CrA)
Number of subjects: 200
Study 21269553 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley's manoeuvre alone
Number of subjects: 51
Study 21269553 — intervention group
Group type: COMPARATOR
Intervention: Epley's manoeuvre plus labyrinthine sedative
Number of subjects: 51
Study 19167712 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg/d
Number of subjects: 35
Study 19167712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19167712 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg/d
Number of subjects: 35
Study 17210208 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment nerve block
Number of subjects: 55
Study 17210208 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 55
Study 15502038 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg mivacurium (MV group, n = 10)
Number of subjects: 20
Study 15502038 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg/kg pancuronium (PC group, n = 10)
Number of subjects: 20
Study 11522179 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HIV-1 RNA levels
Number of subjects: 102
Study 10661294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support with enriched food supplements
Number of subjects: 0
Study 10661294 — intervention group
Group type: COMPARATOR
Intervention: Standard care without nutritional intervention
Number of subjects: 0
Study 7945560 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial whole-body ultraviolet radiation (UVR) for 6 weeks
Number of subjects: 14
Study 7945560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study 3673913 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 200
Study 3673913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 31835966 — intervention group
Group type: EXPERIMENTAL
Intervention: FINE program (smoking cessation support services provided by trained pharmacists)
Number of subjects: 5
Study 31835966 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 5
Study 29813097 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐vitamins alone (560 μg of 5‐methyl‐THF, 3 mg of vitamin B6 and 20 μg of vitamin B12)
Number of subjects: 2381
Study 29813097 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 fatty acids alone (600 mg of EPA and DHA in a 2:1 ratio)
Number of subjects: 2381
Study 29813097 — intervention group
Group type: EXPERIMENTAL
Intervention: B‐vitamins and n‐3 fatty acids
Number of subjects: 2381
Study 29813097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2381
Study 27578110 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched fish oil (2.4 g per day for 8 weeks)
Number of subjects: 72
Study 27578110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25703424 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 0
Study 25703424 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 24024327 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200‐Kcal basic Chinese traditional diet (BTCD)
Number of subjects: 694
Study 24024327 — intervention group
Group type: COMPARATOR
Intervention: 1200‐Kcal standard western diet
Number of subjects: 694
Study 20384434 — intervention group
Group type: EXPERIMENTAL
Intervention: Full model (FM) including age, sex, body mass index (BMI), systolic and diastolic blood pressure, smoking status, and 38 SNPs.
Number of subjects: 485
Study 20384434 — intervention group
Group type: COMPARATOR
Intervention: Reduced model (RM) without SNPs.
Number of subjects: 485
Study 18544144 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular brachial plexus block
Number of subjects: 80
Study 18544144 — intervention group
Group type: COMPARATOR
Intervention: Infraclavicular brachial plexus block
Number of subjects: 80
Study 18544144 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both approaches
Number of subjects: 80
Study 16644505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivatvongs technique
Number of subjects: 112
Study 16644505 — intervention group
Group type: COMPARATOR
Intervention: Conventional local anaesthetic infiltration
Number of subjects: 112
Study 16191241 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study 10966542 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-lead system
Number of subjects: 16
Study 10966542 — intervention group
Group type: COMPARATOR
Intervention: 3-lead system
Number of subjects: 16
Study 10966542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 16
Study 8792890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine aerosol 500 mg (100 mg/ml; Xylocain aerosol, ASTRA, Sweden)
Number of subjects: 30
Study 8792890 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 30
Study 1627204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 631
Study 1627204 — intervention group
Group type: COMPARATOR
Intervention: Miconazole 2% cream
Number of subjects: 631
Study 6398021 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive drug therapy with plasmapheresis (PP)
Number of subjects: 0
Study 30941124 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell therapy targeting HLA‐A02 restricted HIV antigen epitopes
Number of subjects: 28
Study 30941124 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 30069604 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot condition (34.9 ± 0.3 °C, 36.6 ± 6.2% RH)
Number of subjects: 15
Study 30069604 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition (22.4 ± 0.1 °C, 40.4 ± 6.5% RH)
Number of subjects: 15
Study 26971352 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive/resin cement with selective enamel etching (SB+E)
Number of subjects: 50
Study 26971352 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal adhesive/resin cement without selective enamel etching (SB-E)
Number of subjects: 50
Study 26971352 — intervention group
Group type: COMPARATOR
Intervention: Self-adhesive resin cement (RelyX Unicem 2, RXU2)
Number of subjects: 50
Study 24215388 — intervention group
Group type: EXPERIMENTAL
Intervention: Single incision laparoscopic cholecystectomy (SILC)
Number of subjects: 90
Study 24215388 — intervention group
Group type: COMPARATOR
Intervention: 3-port laparoscopic cholecystectomy
Number of subjects: 90
Study 24215388 — intervention group
Group type: COMPARATOR
Intervention: 4-port laparoscopic cholecystectomy
Number of subjects: 90
Study 22193561 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon β‐1b
Number of subjects: 0
Study 19666685 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel contour enhanced funnel plots
Number of subjects: 0
Study 19666685 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression based adjustment method
Number of subjects: 0
Study 19666685 — intervention group
Group type: COMPARATOR
Intervention: Intention to treat analysis
Number of subjects: 0
Study 17568252 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of daily 6x15 min ergometer training at submaximal intensity plus 1 h/week group exercise session followed by 5 months of home-based ergometer training of 30 min/day plus 1 h/week group exercise session
Number of subjects: 39
Study 17568252 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 months of home-based exercise training of moderate frequency and duration
Number of subjects: 39
Study 17568252 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 39
Study 15878101 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy in 1 fraction (8/1)
Number of subjects: 272
Study 15878101 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy in 5 fractions (20/5)
Number of subjects: 272
Study 12062596 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (vinblastine 5 mg/m(2) i.v. bolus weekly for the first 5 weeks, and cisplatin, 100 mg/m(2) i.v. on Days 1 and 29) followed by concurrent chemotherapy/radiotherapy (cisplatin 75 mg/m(2) i.v. on Days 50, 71, and 92) during thoracic radiotherapy (63 Gy in 34 fractions during 7 weeks starting on Day 50)
Number of subjects: 163
Study 12062596 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemotherapy and hyperfractionated radiotherapy starting on Day 1 with a total dose of 69.6 Gy in 58 fractions during 6 weeks, 1.2 Gy/fraction b.i.d. (cisplatin, 50 mg/m(2) i.v. on Days 1 and 8, and oral VP‐16, 50 mg b.i.d. for 10 days only on the days of thoracic radiotherapy repeated on Day 29)
Number of subjects: 163
Study 9593141 — intervention group
Group type: EXPERIMENTAL
Intervention: sorivudine (40 mg once daily)
Number of subjects: 170
Study 9593141 — intervention group
Group type: COMPARATOR
Intervention: acyclovir (800 mg five times daily)
Number of subjects: 170